vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength

vTv Therapeutics ( (VTVT) ) just unveiled an update.

On February 26, 2026, vTv Therapeutics posted an updated corporate slide presentation outlining the progress of cadisegliatin, its late-stage oral adjunctive therapy candidate for type 1 diabetes, and its broader pipeline. The company highlighted the unmet need in type 1 diabetes, where about 75% of U.S. patients fail to reach recommended HbA1c targets and no oral adjunctive therapies are approved, positioning cadisegliatin—now in Phase 3 with topline CATT1 data expected in the second half of 2026, and backed by prior Phase 1 and Phase 2 data and FDA Breakthrough designation—as a potential first-in-class solution.

The presentation also emphasized vTv’s financial strength, citing $98.5 million in cash as of September 30, 2025, plus $20 million received on February 2, 2026, supporting operations well past the anticipated Phase 3 readout. With a seasoned leadership team and a pipeline of differentiated assets in multiple therapeutic areas, the update signals that vTv is positioning itself to capitalize on a large, long-underserved market in type 1 diabetes while pursuing additional partnering and funding opportunities across its portfolio.

The most recent analyst rating on (VTVT) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.

Spark’s Take on VTVT Stock

According to Spark, TipRanks’ AI Analyst, VTVT is a Neutral.

Score is held back primarily by very weak financial performance—minimal revenue, large ongoing losses, and persistent cash burn—despite low debt. Technicals are mixed (longer-term trend above key moving averages but softer near-term momentum), and valuation is constrained by negative earnings. A notable positive is the recent partnership amendment that could provide meaningful non-dilutive funding and milestone/royalty upside.

To see Spark’s full report on VTVT stock, click here.

More about vTv Therapeutics

vTv Therapeutics, Inc. is a Nasdaq-listed biopharmaceutical company focused on developing therapies for diabetes and metabolic diseases. Its late-stage portfolio is led by cadisegliatin, an oral adjunctive candidate for type 1 diabetes, and is supported by additional clinical-stage assets in immunology, inflammation, metabolism and oncology, targeting large unmet medical needs and potential non-dilutive funding opportunities.

The company is led by an experienced management team with deep expertise in developing and commercializing metabolic and diabetes treatments. vTv reports a strong balance sheet, with $98.5 million in cash as of September 30, 2025, and an additional $20 million received on February 2, 2026, providing financial runway beyond upcoming Phase 3 data readouts.

Average Trading Volume: 20,248

Technical Sentiment Signal: Buy

Current Market Cap: $166.5M

For a thorough assessment of VTVT stock, go to TipRanks’ Stock Analysis page.